美沙拉嗪联合低分子肝素治疗溃疡性结肠炎临床疗效观察

目的：观察美沙拉嗪联合低分子肝素治疗溃疡性结肠炎的临床疗效。方法：选择40例中重度溃疡性结肠炎患者，随机分为两组：A组为对照组，20例，美沙拉嗪，4g／d，日四次口服治疗，B组为实验组，20例，美沙拉嗪，4g／d，日四口服，联合低分子肝素，5000单影日二次皮下注射1周治疗。2周后观察治疗前后的结肠镜下改变及血清CRP变化。结果：实验组的总有效率高于对照组，但无明显统计学差异；实验组的完全缓解率高于对照组且有统计学意义。实验组的血清CRP水平明显降低，随访6个月后仍维持较低水平。结论：在中重度溃疡性结肠炎治疗中，美沙拉嗪联合低分子肝素临床疗效要优于单用美沙拉嗪，完全缓解率高，且远期疗效较好。

The curative effect of moderate and severe ulcerative colitis treated by mesalazine combined with low molecule heparin

Objective： To evaluate the curative effect of ulcerative colitis treated by Mesalazine combined with low molecule heparin. Methods： 40 patients with moderate and severe ulcerative colitis were divided into 2 groups randomly. A group is control group, 20 patients, mesalazine was given orally as 4g/d, four times a day; B group is experimental group, 20 patients, mesalazine was given orally as 4g/d, four times a day, oral taken, combined with low - molecule heparin 5000U/bid subcutaneous injection for 1 week. The changes of serum CRP and it under eolonscope were evaluated Results： The effective rate of the experimental group was a little higher than that of the control group. So there is no statistical significance. The complete remission rate of the experimental group is higher than that of the control group, there is statistical significance. The serum CRP value was decrease significantly in experimental group, even was still low in next 6 month. Conclusion： the effect of mesalazine combined with low molecule heparin was higher than that of mesalazine alone for the patients with moderate and severe ulcerative colitis and long - term therapeutic effect was very good.